Clinical Trial Update: Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the effects of co-administering canagliflozin (300 mg) and phentermine (15 mg) with placebo in non-diabetic overweight and obese adults…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Canagliflozin (Invokana) (canagliflozin)
• Phentermine (Phentermine)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Obesity | Phase 2 | Status: COMPLETED | Results posted: 2016-10-06